ANZCTR search results

SCANSTROKE study will assess the utility of a software tool to identify ED patients suitable for acute stroke treatment. The tool will assess language present in the documented notes by ED triage clinicians. This will be compared against whether patients were actually activated as a stroke code at the time and whether they ended up having a stroke as their final diagnosis.

The purpose of this research study is to investigate how safe GIM-407 is when it is administered to adult participants with Coeliac Disease and how this investigational treatment is absorbed and processed by the human body. This study will also look to see if any indicators of the disease are affected by GIM-407. Participants will receive either GIM-407 or a placebo, and be asked to drink a slurry containing a measured amount of gluten each day for several weeks (this is called a 'gluten challenge'), under close medical supervision. The gluten challenge is done to monitor how their body responds to gluten while they are receiving the study treatment.

This pilot safety clinical trial proposes an amended shortened version of the apomorphine pen initiation for patients with no prior history of PD medication induced nausea. This streamlined approach has the potential to significantly improve the initiation process for PD patients, making it quicker without compromising safety. The initial dose will be in line with current recommendations of 2mg (0.2mL) without the presence of an antinausea medication. The dose will be slowly titrated as required until the optimum dosage has been reached. This study will provide valuable insights and pave the way for protocol adjustments that benefit both patients and healthcare providers.

This study is a prospective, single-arm, single-centre, first-in-human clinical investigation evaluating the safety and feasibility of a new bronchoscopic ultrasound system for the survey and sampling of mediastinal and hilar lymph node stations in patients with confirmed or suspected lung cancer. Who is it for? You may be eligible for this study if you are aged 21 years or older and have a confirmed diagnosis of lung cancer or have been assessed by the Investigator as having a high clinical suspicion and indicated for staging lung cancer. Study details In this Phase 2 study, all participants will be sedated and undergo a standard bronchoscopic procedure. Survey and Sampling of lymph node stations will be conducted using the investigational device. Follow-up visits will be at 1-week, 30 days and 3 months post-procedure (chart review only). All participants are monitored for adverse events and outcomes related to the procedure and device through 30 days post procedure. It is hoped that findings from this study will help researchers and clinicians determine whether use of this new system is safe and feasible.

Here, we aim to evaluate the app-version of a simple, memory-based program MemFlex. A paper version of the program has been previously evaluated in young people and was demonstrated to improve symptoms of depression and ameliorate cognitive difficulties that predict prognosis and impede the efficacy of psychological therapy (Mirabolfathi et al., 2024). Our key aim is to determine the acceptability of the app-based delivery of MemFlex to young people, as well as assess whether the program may improve symptoms of depression and autobiographical memory bias, known to be a cognitive predictor of mental ill-health.

This study is testing whether people recover just as safely, or better after a less restrictive, faster rehabilitation program following a minimally invasive (“key-hole”) lumbar discectomy for a herniated disc. Endoscopic surgery uses smaller cuts than traditional microdiscectomy and may let patients return to normal activities sooner, but rehabilitation advice is often still based on cautious programs designed for more invasive procedures. Participants will follow one of three pathways: microdiscectomy with a standard rehabilitation program, or endoscopic discectomy with participants being randomly assigned to either a standard rehabilitation program or a faster, self-guided approach. To prevent expectations affecting their self-reported questionnaires, participants having endoscopic surgery won’t be told which rehabilitation plan they’re on. Recovery will be checked every two weeks for 12 weeks, and then again at 1 and 2 years after surgery, using questionnaires, patient-reported measures, and simple physical tests at the clinic and/or at home. The main goal of this study is to see if faster rehabilitation helps a same number or more patients to achieve minimal clinically important differences in the Oswestry Disability Index by 12 weeks post-surgery for patients undergoing endoscopic discectomy.

This study looks at whether people recover better after anterior-to-psoas (ATP) lumbar fusion surgery when they follow a less restrictive rehabilitation plan. Although ATP is a minimally invasive technique that may allow earlier movement and return to activity, rehabilitation advice is often still based on older, more cautious programs designed for more invasive surgery. Before surgery, participants will be randomly assigned before surgery to either a standard or an accelerated rehabilitation program. A multidisciplinary clinical team will support recovery in both groups, with wound healing and patient safety prioritised throughout. Recovery will be checked every two weeks for 12 weeks, and at 1 and 2 years after surgery using questionnaires, patient-reported outcome measures, and functional tests. The primary objective of this study is to determine whether the accelerated rehabilitation group results in equal or more patients achieving minimal clinically important differences in Oswestry Disability Index by 12 weeks post-surgery for patients undergoing ATP lumbar fusion surgery.

This study will evaluate whether a pop-up “Heart Health Check” can be used to feasibly and acceptably screen adults in the Springfield community for previously unrecognised cardiometabolic risk. Adults aged 18 years and over who attend a pop-up screening session will complete a brief questionnaire and screening measures including glycated haemoglobin, blood pressure, body measurements, and liver health assessment using FibroScan, and will receive a printed summary of their results. Participants will also be invited to complete a brief online follow-up questionnaire 2 weeks later about any health-related actions they took after screening, how useful they found the screening, and any barriers to follow-up. The study is expected to provide early evidence about the feasibility and acceptability of this community screening model, the burden of cardiometabolic risk identified, and whether receiving personalised screening results prompts short-term follow-up action. It is hypothesised that the pop-up screening model will be feasible and acceptable and will identify a meaningful burden of previously unrecognised cardiometabolic risk in this community

Currently, endometriosis is diagnosed by invasive surgery (laparoscopically followed by histopathology), or severe disease may be detected by imaging modalities (ultrasound or MRI). No early, non-invasive diagnostic test exists for endometriosis. This prospective study aims to explore the use of fluoro-17beta-estradiol PET/CT imaging as a potential non-invasive, early diagnostic test for endometriosis relative to surgical/histological outcomes. We hypothesize that PET/CT imaging with fluoro-17beta-estradiol has potential application in the diagnosis of endometriosis.

What the study is about: This study aims to find out whether a short course of the medicines polatuzumab vedotin (PV) and rituximab, with or without targeted radiotherapy, can better control lymphoma while patients wait for their personalised CAR-T cell therapy with Tisa-cel. Many people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have fast-growing disease, and some may become too unwell to receive CAR-T treatment during the manufacturing period. Early control of the lymphoma during this waiting time—called bridging therapy—may help improve the chances that CAR-T therapy works well. Who is this trial for: • 18 years of age or older with a prior diagnosis of DLBCL, • Have had the cancer return after two or more treatments, • You are eligible to receive CAR-T cell treatment and have already had leukapheresis. Study Details: This is a single arm, open label, phase 2 study. Participants will receive bridging therapy before CAR-T cell treatment with: • Polatuzumab vedotin (PV) administered intravenous (IV) on Day 1. • Rituximab administered IV on Day 1. • Depending on the wait time for Tisa-cel manufacture, a 2nd dose of PV and rituximab can be administered on day 22. • Radiotherapy may be added if your doctor recommends it. This study will recruit a total 47 participants across Australia, Taiwan, Hong Kong, and South Korea. What is hoped from it: This trial will help determine whether a more effective and tolerable bridging strategy can keep patients well enough for CAR-T therapy and improve their long-term outcomes.